Correction: *The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. A meta-analysis and functional study*

McGonagle DG, McInnes IB, Kirkham BW, *et al.* The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. A meta-analysis and functional study. *Ann of Rheum Dis* 2019;78:1167–78. doi: 10.1136/annrheumdis-2019-215356.

Figure 4 is amended to reflect the lack of definitive, controlled clinical evidence of prevention of structural progression by secukinumab in axial spondyloarthritis.

	Secukinumab ^{12–16,20,21,168,232–235}	Ixekizumab ^{17–19,169,236,237}
Approved indications	Psoriasis, PsA, AS	Psoriasis, PsA
MoA	Fully-human anti-IL-17A antibody	Humanised anti-IL-17A antibody
PsA		
Peripheral arthritis	●	●
Enthesitis	●	●
Dactylitis	●	●
Skin	●	●
Nail	●	●
Axial disease	●	⦿
Structural progression	●	●
AS		
Signs and symptoms	●	●
Disease activity	●	●
Function	●	●
Structural progression	●	●
Non-radiographic axial SpA	●	●
Psoriasis	●	●
Crohn's disease	●	⦿
Uveitis ^a	●	⦿

● Effective ● Under investigation ● Not effective ⦿ Not assessed

OPEN ACCESS

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Ann Rheum Dis 2020;79. doi:10.1136/annrheumdis-2019-215356corr1